Is the price fair?
What MEDP's price assumes
Medpace Holdings, Inc. trades at 36.4× earnings against 35.3× for the median Diagnostics & Research name, more expensive than its own group.
36.4
Trailing P/E · Diagnostics & Research median 35.3 · 1.03× the median: the market pays up for this one
- Price / sales
- 5.19
Price / sales · as of 2026-Q1
- Free cash flow yield
- 5.4%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +4.7%
Growth the price implies · The price pays for +4.7% free cash flow growth a year for a decade; the business has delivered +24% a year over the last three.
Details›
- Price / book2026-Q1
- 23.2
- Healthcare median P/E362 names
- 31.5
- Diagnostics & Research median P/E29 names
- 35.3
- Free cash flow, trailing twelve months
- $707M
- Market capitalisation
- $13.1B
- 3-year revenue growth
- +18%
- 3-year free cash flow growth
- +24%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $504.20 |
| Its own P/E history, median | $537.77 |
| Its own P/E history, upper quartile | $611.76 |
| 52-week range | $393.42 – $620.70 |
| Today | $619.99 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #3 of 29 by Smart Score